Advances in Later-Line Management of Relapsed/Refractory Follicular Lymphoma.

Citation metadata

Author: Sameh Gaballa
Date: June 2021
From: Oncology(Vol. 35, Issue 6)
Publisher: Intellisphere, LLC
Document Type: Disease/Disorder overview
Length: 640 words
Lexile Measure: 1410L

Document controls

Main content

Article Preview :

Follicular lymphoma (FL) is an indolent B-cell lymphoproliferative disease that accounts for approximately 20% of all cases of non-Hodgkin lymphoma. (1) CancerNetwork[R] met with Sameh Gaballa, MD, of Mofitt Cancer Center in Tampa, Florida, to discuss the management of relapsed/refractory (R/R) FL. Gaballa said that patients with FL are not expected to be cured after frontline therapy. Most patients relapse, although he noted that approximately 80% of patients remain in remission for 2 or more years after chemoimmunotherapy and have a very good prognosis. Patients who experience progression of disease within 2 years after frontline (POD24) have a worse prognosis.

Treatment of Relapsed/Refractory Follicular Lymphoma

The treatment goal with R/R FL is to control symptoms, said Gaballa. "You're not going to cure [patients with R/R FL]," he said. "If they have bulky disease, if they have symptomatic disease, then those are the patients who you would consider treatment for. Otherwise, you could just observe them."

Regarding first-line treatment of R/R...

Source Citation

Source Citation   

Gale Document Number: GALE|A677572508